Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can lowering inflammation protect your heart? new study explores link in arthritis patients

NCT ID NCT02714881

Knowledge-focused Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how reducing inflammation might lower heart disease risk in people with rheumatoid arthritis. Researchers measured heart blood flow in 74 patients before and after treatment with certolizumab, a drug that fights inflammation. The goal was to see if better control of arthritis inflammation could improve heart health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Certolizumab
What this could lead to
If successful, this could show that controlling inflammation improves heart function in rheumatoid arthritis patients, pointing toward better cardiovascular risk management.
What could go wrong
This is a small, completed observational study with only 74 participants, so results may not apply to everyone. It does not test a new treatment directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

74 people

The number who actually took part.

Started

Oct 2016

Finished

Dec 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with active RA who are biologic naive

Ages

35 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * RA diagnosed by a rheumatologist * Fulfills the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Criteria for RA * Age\>35 * Active RA as defined by treating rheumatologist * Biologic DMARD naive Exclusion Criteria: * Patients on statin or PCSK9 inhibitor therapy * Corticosteroid therapy \>10mg prednisone or its equivalent as a maintenance treatment * Pregnancy * Unstable angina (chest pain) or shortness of breath * Severe valvular heart disease * Myocarditis * Pericarditis * Asthma with active wheezing * History of lymphoproliferative disease or melanoma (stage two or higher), active malignancy, or cancer treatment in the last 5 years * Active infectious disease (HIV, Tuberculosis, or Hepatitis B/C)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular disease Rheumatoid arthritis

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.